BMY patent cliff and pipeline

Bristol Myers Squibb (BMY) is facing a significant patent cliff, with key drugs like Eliquis and Opdivo set to lose exclusivity in the coming years. This will expose BMY to generic competition, potentially leading to substantial revenue losses. The company's stock has been deemed cheap by some analysts due to these upcoming headwinds, but others caution that BMY's growth portfolio may not fully offset these losses. BMY's stock price has been volatile, trading around $58 as of April 2026.

The pharmaceutical sector is affected, with BMY's peers and investors closely watching the company's ability to navigate this patent cliff. BMY's stock performance could influence investor sentiment towards other pharma companies with similar challenges. The company's dividend program, a key attraction for income investors, may also face scrutiny given the revenue pressures.

Investors should watch for BMY's Q2 2026 earnings report (expected in late July 2026) to assess the impact of patent expirations on revenue and earnings. Additionally, regulatory decisions on BMY's pipeline drugs, such as liso-cel for lymphoma and tezanuumab for osteoporosis, will be crucial. These drugs could help BMY offset patent cliff losses if approved and launched successfully. Lastly, investors should monitor BMY's stock price action around the $55 level, as a break below this support could signal further weakness.